NYSE:CANF Can-Fite BioPharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.90 -0.02 (-2.17%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.86▼$0.9350-Day Range$0.83▼$1.0252-Week Range$0.78▼$2.60Volume214,455 shsAverage Volume389,261 shsMarket Capitalization$24.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Can-Fite BioPharma Stock Forecast (MarketRank)Analyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.35 out of 5 starsMedical Sector1385th out of 1,429 stocksPharmaceutical Preparations Industry666th out of 682 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Can-Fite BioPharma. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for CANF. Previous Next 0.0 Dividend Strength Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CANF. Previous Next 1.1 News and Social Media Coverage News SentimentCan-Fite BioPharma has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Can-Fite BioPharma this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.78% of the stock of Can-Fite BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Can-Fite BioPharma (NYSE:CANF)Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.comJune 28, 2022 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) & Can-Fite BioPharma (NYSE:CANF) Financial ComparisonJune 24, 2022 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972 3 924 1114Fax972-3924-9378Employees8Year FoundedN/ACompany Calendar Last Earnings5/26/2022Today7/01/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12.61 million Net Margins-1,447.36% Pretax Margin-1,478.90% Return on Equity-132.72% Return on Assets-84.89% Debt Debt-to-Equity RatioN/A Current Ratio6.09 Quick Ratio6.09 Sales & Book Value Annual Sales$850 thousand Price / Sales28.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book1.70Miscellaneous Outstanding Shares27,192,000Free FloatN/AMarket Cap$24.47 million OptionableNot Optionable Beta1.86 Can-Fite BioPharma Frequently Asked Questions How has Can-Fite BioPharma's stock performed in 2022? Can-Fite BioPharma's stock was trading at $1.20 at the beginning of the year. Since then, CANF stock has decreased by 25.0% and is now trading at $0.90. View the best growth stocks for 2022 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings data on Thursday, May, 26th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The business earned $0.21 million during the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,447.36% and a negative trailing twelve-month return on equity of 132.72%. View Can-Fite BioPharma's earnings history. Who are Can-Fite BioPharma's key executives? Can-Fite BioPharma's management team includes the following people: Dr. Pnina Fishman Ph.D., Scientific Founder, CEO & Director (Age 74, Pay $644k)Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 58, Pay $416k)Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 50, Pay $317k)Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 68)Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D., Sr. Clinical Advisor Who are some of Can-Fite BioPharma's key competitors? Some companies that are related to Can-Fite BioPharma include Checkpoint Therapeutics (CKPT), ImmunoPrecise Antibodies (IPA), NervGen Pharma (NGENF), BriaCell Therapeutics (BCTX), Summit Therapeutics (SMMT), Eliem Therapeutics (ELYM), Anixa Biosciences (ANIX), Capricor Therapeutics (CAPR), Sol-Gel Technologies (SLGL), Clearside Biomedical (CLSD), TherapeuticsMD (TXMD), GT Biopharma (GTBP), Adagene (ADAG), Cue Biopharma (CUE) and Fortress Biotech (FBIO). View all of CANF's competitors. What is Can-Fite BioPharma's stock symbol? Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF." How do I buy shares of Can-Fite BioPharma? Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Can-Fite BioPharma's stock price today? One share of CANF stock can currently be purchased for approximately $0.90. How much money does Can-Fite BioPharma make? Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $24.47 million and generates $850 thousand in revenue each year. The company earns $-12.61 million in net income (profit) each year or ($0.66) on an earnings per share basis. How many employees does Can-Fite BioPharma have? Can-Fite BioPharma employs 8 workers across the globe. How can I contact Can-Fite BioPharma? Can-Fite BioPharma's mailing address is 10 BAREKET STREET KIRYAT MATALON P.O. BOX 7537, PETACH TIKVA L3, 4951778. The official website for Can-Fite BioPharma is www.canfite.com. The company can be reached via phone at 972 3 924 1114, via email at [email protected], or via fax at 972-3924-9378. This page (NYSE:CANF) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
